NASDAQ$ATAI
AtaiBeckley Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Atai reported first quarter 2023 financial results and provided corporate updates.
Atai Life Sciences reported a net loss of $33.1 million for the first quarter of 2023. The company's cash and cash equivalents totaled $249.9 million as of March 31, 2023, which is expected to fund operations into 1H 2026.
- First patient dosed in the Phase 2b study of RL-007 in Cognitive Impairment Associated with Schizophrenia.
- Presented PD data from the completed Phase 1 study of GRX-917, suggesting potential anxiolytic effects without significant sedative effects.
- VLS-01 was well-tolerated in Parts 1 and 2 of the ongoing Phase 1 study, with an amended protocol to expand into Part 3 to optimize PK and PD.
- Acceleration of the Pivotal Trial 1 (COMP 005) part of the Phase 3 program in TRD, with topline data now expected in the summer of 2024.
Headline financials
Revenue & EPS history
Atai · Revenue · Quarterly
$37K
Forward guidance
The Company expects its cash position and committed term loan funding will be sufficient to fund operations into 1H 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
+0.7%
Avg return
Earnings day
+3.3%
Avg return
5 days after
+2.2%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+15.1%
Q4 2022
Best reaction
-17.7%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.5% | -0.5% | — | |
| Q4 2026 | -1.1% | +14.7% | +7.1% | |
| Q3 2025 | -2.0% | -10.6% | -3.2% | |
| Q2 2025 | -1.2% | -2.0% | +14.3% | |
| Q1 2025 | +1.4% | +30.5% | +49.6% | |
| Q4 2024 | -1.4% | -2.0% | -4.1% | |
| Q3 2024 | -6.2% | +14.4% | -6.8% | |
| Q2 2024 | -5.6% | -1.6% | -0.8% | |
| Q1 2024 | -2.6% | -9.4% | -28.3% | |
| Q4 2023 | +3.9% | +4.5% | +7.8% | |
| Q3 2023 | +4.3% | -3.5% | +11.3% | |
| Q2 2023 | -4.5% | -8.5% | -18.8% | |
| Q1 2023 | -5.0% | -3.0% | -12.5% | |
| Q4 2022 | +15.1% | +33.6% | +82.4% | |
| Q3 2022 | +1.1% | +5.9% | +17.6% | |
| Q2 2022 | +4.1% | -1.3% | -12.7% | |
| Q1 2022 | +13.2% | +9.9% | -9.1% | |
| Q4 2021 | -6.1% | -2.0% | -20.8% | |
| Q3 2021 | -17.7% | -21.9% | -54.3% | |
| Q1 2021 | +10.2% | +13.1% | +12.7% | |
| Q2 2021 | +13.0% | +9.0% | +11.5% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro